315 related articles for article (PubMed ID: 32421446)
1. Dermatologic Adverse Events of Systemic Anticancer Therapies: Cytotoxic Chemotherapy, Targeted Therapy, and Immunotherapy.
Deutsch A; Leboeuf NR; Lacouture ME; McLellan BN
Am Soc Clin Oncol Educ Book; 2020 May; 40():485-500. PubMed ID: 32421446
[TBL] [Abstract][Full Text] [Related]
2. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Lacouture M; Sibaud V
Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies.
Ng CY; Chen CB; Wu MY; Wu J; Yang CH; Hui RC; Chang YC; Lu CW
J Immunol Res; 2018; 2018():5376476. PubMed ID: 29577050
[TBL] [Abstract][Full Text] [Related]
4. What's the Price? Toxicities of Targeted Therapies in Breast Cancer Care.
Anders CK; LeBoeuf NR; Bashoura L; Faiz SA; Shariff AI; Thomas A
Am Soc Clin Oncol Educ Book; 2020 May; 40():55-70. PubMed ID: 32421449
[TBL] [Abstract][Full Text] [Related]
5. Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology.
Grávalos C; Sanmartín O; Gúrpide A; España A; Majem M; Suh Oh HJ; Aragón I; Segura S; Beato C; Botella R
Clin Transl Oncol; 2019 May; 21(5):556-571. PubMed ID: 30284232
[TBL] [Abstract][Full Text] [Related]
6. Advances in the management of cutaneous toxicities of targeted therapies.
Robert C; Sibaud V; Mateus C; Cherpelis BS
Semin Oncol; 2012 Apr; 39(2):227-40. PubMed ID: 22484194
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous manifestations of nontargeted and targeted chemotherapies.
Shi VJ; Levy LL; Choi JN
Semin Oncol; 2016 Jun; 43(3):419-25. PubMed ID: 27178698
[TBL] [Abstract][Full Text] [Related]
8. The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature.
Belzer A; Pach JJ; Valido K; Leventhal JS
Am J Clin Dermatol; 2024 May; 25(3):435-445. PubMed ID: 38366030
[TBL] [Abstract][Full Text] [Related]
9. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.
Belum VR; Washington C; Pratilas CA; Sibaud V; Boralevi F; Lacouture ME
Pediatr Blood Cancer; 2015 May; 62(5):798-806. PubMed ID: 25683226
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy in oncology patients and skin: Pharmaceutical and dermocosmetic management.
Varvaresou A; Iakovou K; Mellou F; Myrogiannis D; Papageorgiou S
J Cosmet Dermatol; 2020 Apr; 19(4):782-788. PubMed ID: 31769600
[TBL] [Abstract][Full Text] [Related]
11. Dermatologic toxicities of targeted antineoplastic agents and immune checkpoint inhibitor therapy in pediatric patients: A systematic review.
Liu LY; Teng JMC; Spunt SL; Strelo JL; Kwong BY; Zaba LC
Pediatr Blood Cancer; 2021 Dec; 68(12):e29346. PubMed ID: 34569142
[TBL] [Abstract][Full Text] [Related]
12. Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.
Drilon A; Eaton AA; Schindler K; Gounder MM; Spriggs DR; Harris P; Ivy SP; Iasonos A; Lacouture ME; Hyman DM
Cancer; 2016 Apr; 122(8):1228-37. PubMed ID: 26916138
[TBL] [Abstract][Full Text] [Related]
13. Anticancer therapies associated with secondary cutaneous malignancies: A review of the literature.
Deutsch A; Balagula Y; McLellan BN
J Am Acad Dermatol; 2020 Nov; 83(5):1425-1433. PubMed ID: 32334055
[TBL] [Abstract][Full Text] [Related]
14. Pruritus Associated with Targeted Anticancer Therapies and Their Management.
Wu J; Lacouture ME
Dermatol Clin; 2018 Jul; 36(3):315-324. PubMed ID: 29929603
[TBL] [Abstract][Full Text] [Related]
15. A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines.
Hirakawa A; Sudo K; Yonemori K; Sadachi R; Kinoshita F; Kobayashi Y; Okuma HS; Kawachi A; Tamura K; Fujiwara Y; Rubinstein L; Takebe N
Clin Pharmacol Ther; 2019 Oct; 106(4):803-809. PubMed ID: 30927439
[TBL] [Abstract][Full Text] [Related]
16. [Description of adverse events in publications of clinical trials: much room for improvement.].
Di Maio M; Antonuzzo A; Bossi P
Recenti Prog Med; 2019; 110(7):323-324. PubMed ID: 31379365
[TBL] [Abstract][Full Text] [Related]
17. Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management.
Belum VR; Cercek A; Sanz-Motilva V; Lacouture ME
Curr Treat Options Oncol; 2013 Sep; 14(3):389-404. PubMed ID: 23996476
[TBL] [Abstract][Full Text] [Related]
18. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
19. [Dermatologic adverse events of the new targeted anticancer therapies used in oncodermatology].
Sibaud V; Delord JP; Chevreau C; Gangloff D; Garrido-Stowhas I
Ann Chir Plast Esthet; 2012 Apr; 57(2):106-13. PubMed ID: 22425393
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
